Biotechnology drug developer Bionomics has sold its French subsidiaries to focus on commercialising its lead drug candidate to treat post traumatic stress disorder. The company sold Neurofit and Prestwick Chemical which carry out contract research to Domain Therapeutics. Consideration for the sale was $3 million which is the amount of inter-company debt owed by Bionomics…
Biopharmaceutical developer Bionomics (ASX: BNO) has received a $5.2 million R&D Tax Incentive Refund for 2018/2019 recognising its intense product development efforts. The company, which is developing a number of novel drug candidates based its unique ionX platform technology, appears to have received one of the largest refunds for the year. While most young drug…
Zip Water appoints new Director of Marketing and Innovation Drinking water systems manufacturer Zip Water has appointed Vivian Zurlo as its new Marketing and Innovation Director ANZ. According to a statement this week, the role will see Zurlo lead strategic marketing initiatives across commercial, residential and service channels, as well as innovation, to further elevate…
SkyKraft set for big December launch Satellite operator Skykraft plans to change the landscape of Air Traffic Management (ATM) in December when its first payload of five ATM satellites will be launched with SpaceX out of Florida. According to the company the 300 kilogram satellite payload will be the largest Australian manufactured space object ever…
ARENA to support regional renewable microgrids A new $50 million Australian Renewable Energy Agency fund will support the deployment of microgrids and renewable energy across regional Australia. First announced in the 2020-21 federal budget, the Regional Australia Microgrid Pilots Program (RAMPP) will fund pilot projects that demonstrate the potential for microgrids to benefit regional and…
DroneShield’s new orders from US and Five Eyes customers Drone detection and countermeasure company DroneShield has announced two new orders, one from an existing customer. The company has received a second order worth $1.1 million from a high profile Government customer from a Five Eyes country which shares intelligence with Australia. DroneShield has also received…
Noxopharm reports new treatment for prostate cancer Pharmaceutical developer Noxopharm has claimed a combination of two existing drugs has emerged as a major new treatment for prostate cancer. The company said its Veyonda treatment for late-stage cancers combined with Novartis’ Lu-PSMA-617 resulted in half of patients suffering end stage (Stage 4) disease surviving at least…
DevelopmentWA seeks interest in robotics and automation zone DevelopmentWA is seeking Expression of Interest (EOI) from businesses looking to be involved or have access to the test beds and future facilities of an automation and robotics precinct being developed at a site 40 kilometres north of Perth. The 51 hectare site, which is adjacent to…
Anti depression drug developer Bionomics completes equity raising Bionomics has successfully completed an over-subscribed equity raising from current shareholders, raising $2.2 million before costs. The raising will accelerate the commercialisation of the company’s drug candidate, BNC210 for the treatment of post traumatic stress disorder. The company is also developing drugs for the treatment of pain,…
Next Science raise $15 million cash from investors Anti-microbial drug development company Next Science has completed a $15 million capital raising, with the closure of a $5 million share purchase plan. The raising was $4.2 million over-subscribed. This follows an earlier raising from institutional investors. The cash will help fund the commercial release in the…
